Table 1.
Baseline characteristics for the examined early rheumatoid arthritis patients. Results are given in mean (± standard deviation) for continuous variables and numbers (percentages) for categorical variables.
| Adalimumab + Methotrexate (N = 214) |
Methotrexate Monotherapy (N = 188) |
|
|---|---|---|
| Demographic characteristics | ||
| Age (years) | 51.8 (14.3) | 52.6 (13.2) |
| Female % | 152 (71.0) | 137 (72.9) |
| Clinical characteristics | ||
| Disease duration (years) | 0.7 (0.8) | 0.8 (0.9) |
| Previously taken DMARDs % | 69 (32.2) | 56 (29.8) |
| Previously taken corticosteroids % | 79 (36.9) | 64 (34.0) |
| Tender joint count (0-66) | 30.5 (14.6) | 31.9 (14.3) |
| Swollen joint count (0-66) | 21.4 (11.4) | 22.5 (12.1) |
| C-reactive protein (mg/l) | 40.2 (42.4) | 40.4 (40.9) |
| HAQ (0-3) | 1.5 (0.6) | 1.5 (0.7) |
| DAS28 | 6.3 (0.9) | 6.3 (0.9) |
| DXR-MCI (mg/cm2) | 0.45 (0.09) | 0.45 (0.09) |
DMARDs = disease modifying anti-rheumatic drugs; HAQ = Health Assessment Questionnaire; DAS28 = 28-joint disease activity score; DXR = Digital X-ray radiogrammetry; MCI = metacarpal cortical index.